Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Novembre 2014
2e colloque de l’ITMO Santé publique – Médecine « personnalisée » et innovations biomédicales : enjeux de santé publique, économiques, éthiques et sociaux (Paris, 5 décembre 2013)
Page(s) 32 - 35
Section Session 3. La médecine personnalisée : aggravatrice ou réductrice des inégalités de santé ?
DOI https://doi.org/10.1051/medsci/201430s207
Publié en ligne 17 novembre 2014
  1. Hofstede G, Hofstede GJ, Minkov M. Cultures and organizations. New York : McGraw-Hill, 1997. [Google Scholar]
  2. Holzer B. Political consumerism between individual choice and collective action: social movements, role mobilization and signalling. Int J Cons Stud 2006 ; 30: 405–415. [CrossRef] [Google Scholar]
  3. Lesko LJ. Personalized medicine: elusive dream or imminent reality?. Clin Pharmacol Ther 2007 ; 81 : 807–816. [CrossRef] [PubMed] [Google Scholar]
  4. Hoggatt J. Personalized medicine -trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diagn Ther 2011 ; 15 : 53–55. [CrossRef] [PubMed] [Google Scholar]
  5. Coulter A. Paternalism or partnership? Patients have grown up-and there’s no going back. Br Med J 1999 ; 319 : 719–720. [CrossRef] [PubMed] [Google Scholar]
  6. Seror V, Marino P, Bertucci F, et al. Breast cancer patients’ views on the use of genomic testing to guide decisions about their postoperative chemotherapy. Public Health Genomics 2013 ; 16 : 110–117. [CrossRef] [PubMed] [Google Scholar]
  7. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003 ; 22 : 151–185. [CrossRef] [PubMed] [Google Scholar]
  8. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004 ; 3 : 711–715. [CrossRef] [PubMed] [Google Scholar]
  9. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and drug administration, 1998–2005. Arch Intern Med 2007 ; 167 : 1752–1759. [CrossRef] [PubMed] [Google Scholar]
  10. Blair ED, Stratton EK, Kaufmann M. The economic value of companion diagnostics and stratified medicines. Expert Rev Mol Diagn 2012 ; 12 : 791–794. [CrossRef] [PubMed] [Google Scholar]
  11. Marino P, Bertucci F, Goncalvez A, Seror V. Tests diagnostiques et thérapies ciblées en cancérologie : enjeux économiques. Med Sci (Paris) 2012 ; 28 : 19–23. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Fugel HJ, Nuijten M, Postma M. Stratified medicine, reimbursement issues. Front Pharmacol 2012 ; 3 : 181. [CrossRef] [PubMed] [Google Scholar]
  13. Marino P, Siani C, Bertucci F, et al. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Res Treat 2011 ; 129 : 401–409. [CrossRef] [PubMed] [Google Scholar]
  14. Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov 2009 ; 8 : 279–286. [CrossRef] [PubMed] [Google Scholar]
  15. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers’ coverage of personalized medicine. J Oncol Pract 2011 ; 7 : s18s–s124. [CrossRef] [Google Scholar]
  16. Deverka PA. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 2009 ; 12 : 149–157. [CrossRef] [PubMed] [Google Scholar]
  17. Frank M, Mittendorf T. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness: a systematic review. Pharmacoeconomics 2013 ; 31 : 215–228. [CrossRef] [PubMed] [Google Scholar]
  18. Atherly AJ, Camidge Dr. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 2012 ; 106 : 1100–1106. [CrossRef] [PubMed] [Google Scholar]
  19. Retel VP, Joore MA, Drukker CA, et al. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur J Cancer 2013 ; 49 : 3773–3779. [CrossRef] [PubMed] [Google Scholar]
  20. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006 ; 24 : 5664–5671. [CrossRef] [PubMed] [Google Scholar]
  21. Bertucci F, Borie N, Roche H, et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011 ; 127 : 363–373. [CrossRef] [PubMed] [Google Scholar]
  22. Ladislav S. Toxicities of taxanes. J Cancer Res Ther 2013 ; 9 : 161. [CrossRef] [PubMed] [Google Scholar]
  23. Marino P, Siani C, Roche H, et al. Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Ann Oncol 2010 ; 21 : 1448–1454. [CrossRef] [PubMed] [Google Scholar]
  24. Eichler HG, Bloechl-Daum B, Abadie E, et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 2010 ; 9 : 277–291. [CrossRef] [PubMed] [Google Scholar]
  25. Schreyogg J, Baumler M, Busse R. Balancing adoption and affordability of medical devices in Europe. Health Policy 2009 ; 92 : 218–224. [CrossRef] [PubMed] [Google Scholar]
  26. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2010 ; 94 : 91–100. [CrossRef] [PubMed] [Google Scholar]
  27. Seror V, Elasri K, Avenel E. Premières applications de la pharmacogénomique en oncologie - stratégies industrielles et enjeux de régulation publique. Revue d’Économie Industrielle 2007 ; 120 : 235–252. [CrossRef] [Google Scholar]
  28. Bobinac A, van Exel J, Rutten FF, Brouwer WB. The value of a QALY: individual willingness to pay for health gains under risk. Pharmacoeconomics 2014 ; 32 : 75–86. [CrossRef] [PubMed] [Google Scholar]
  29. Robinson A, Gyrd-Hansen D, Bacon P, et al. Estimating a WTP-based value of a QALY: the chained approach. Soc Sci Med 2013 ; 92 : 92–104. [CrossRef] [PubMed] [Google Scholar]
  30. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev 2007 ; 85 : 108–117, 165. [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.